Video webcast now available on-demandBOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...

Fintel reports that on July 18, 2025, Maxim Group initiated coverage of Akari Therapeutics, Plc - Depositary Receipt () ...

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in ...

Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target Published first on TheFly – the ...

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit Mar. 05, 2024 8:00 AM ET ...

Akari Therapeutics' cash burn of US$17m is about 23% of its US$74m market capitalisation. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at ...

Akari Therapeutics has appointed Abizer Gaslightwala as its new President and Chief Executive Officer, effective April 21, 2025. Gaslightwala brings 25 years of experience in the biotechnology ...

On March 5, 2024, Akari and Peak Bio announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected ...

Multiple insiders secured a larger position in Akari Therapeutics, Plc ( NASDAQ:AKTX ) shares over the last 12 ...

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and ...